Methyl 2,3-dinitrobenzoate | 42087-83-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Methyl 2,3-dinitrobenzoate
• CAS: 42087-83-2
• 化学式: C8H6N2O6
• 分子量: 226.14
• InChiKey: CVECQSXVBHHMBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  118
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• METHOD FOR MANUFACTURING NITROBENZENE COMPOUND
  申请人：Ihara Chemical Industry Co., Ltd.

  公开号：EP3015451A1

  公开（公告）日：2016-05-04

  The purpose of the present invention is to provide an economically favorable, industrialization-suitable method for manufacturing nitrobenzene compounds of general formula (1). A method for manufacturing nitrobenzene compounds of general formula (1): (in the formula, R1 represents a halogen atom; R2, R3, and R4 represent a hydrogen atom, etc.; and R5 represents a halogen atom or alkoxy carbonyl group), the method including the following processes: (i) a process for reacting aniline compounds of general formula (2): (in the formula, R1, R2, R3, R4, and R5 are as previously defined.) in the presence of a metal salt of nitrous acid and an acid, and (ii) a process for reacting the product of process (i) in the presence of a metal salt of nitrous acid and a copper compound; and the total amount of water used in process (ii) being 1.2-2.2 L (liters) with respect to one mole of the compound of general formula (2).

  本发明的目的是提供一种经济上有利的、适合工业化生产的通式（1）硝基苯化合物的制造方法。一种制造通式（1）硝基苯化合物的方法： (式中，R1 代表卤原子；R2、R3 和 R4 代表氢原子等；R5 代表卤原子或烷氧基羰基），该方法包括以下过程：(i) 通式(2)的苯胺化合物的反应过程： (式中，R1、R2、R3、R4 和 R5 如前所定义。)，以及(ii)工艺(i)的产物在亚硝酸金属盐和铜化合物存在下进行反应的工艺；工艺(ii)中相对于一摩尔通式(2)化合物的用水总量为 1.2-2.2 L（升）。
• [EN] ANTI-VIRAL AND ANTI-CANCER AGENTS<br/>[FR] AGENTS ANTIVIRAUX ET ANTICANCEREUX
  申请人：RADOPATH LIMITED

  公开号：WO1996029067A1

  公开（公告）日：1996-09-26

  (EN) 2-Chloro-5-nitrobenzoic acid and various other chloro and nitro substitute benzoic acid derivatives are disclosed for administration in tablet or injectable solution form for treatment of HIV infection. The active compounds have surprising efficacy in various treatment regimes and have particular application to effect regression of lesions in HIV-related Kaposi's sarcoma. The compounds act as costimulators of CD3-triggered T-lymphocyte proliferation to increase the immunological challenge to the retrovirus presented by the natural immune system.(FR) L'invention concerne l'acide 2-chloro-5-nitrobenzoïque et divers autres dérivés de l'acide benzoïque à substitution chloro et nitro, lesquels peuvent être administrés sous forme de comprimé ou de solution injectable pour le traitement de l'infection par VIH. Les composants actifs montrent une efficacité surprenante dans différents régimes de traitement et trouvent une application particulière car ils provoquent une régression des lésions de la maladie de Kaposi apparentée au VIH. Les composés agissent en tant que costimulateurs d'une prolifération des T-lymphocytes déclenchée par CD3, afin de relever le défi immunologique au rétrovirus présenté par le système immunitaire naturel.

  2-氯基-5-硝基苯zoic酸及各种氯基和硝基取代苯zoic酸衍生物被泄露，可用于治疗HIV病毒感染的片剂或注射液形式。这些活性成分在多种治疗方案中展现出惊人疗效，并且在HIV相关Kaposi's sarcoma的病情回归方面有特殊应用。这些化合物通过增强CD3触发的T淋巴细胞增殖来辅助免疫系统对抗逆转录病毒。
• METHOD FOR PRODUCING NITROBENZENE COMPOUND
  申请人：Kumiai Chemical Industry Co., Ltd.

  公开号：EP3015451B1

  公开（公告）日：2018-01-17
• US4506089A
  申请人：——

  公开号：US4506089A

  公开（公告）日：1985-03-19
• [EN] HETEROBIARYLSULPHONAMIDES AND THEIR USE AS PDE 7 INHIBITORS<br/>[FR] HETEROBIARYLSULFONAMIDES ET LEUR UTILISATION COMME INHIBITEURS DE PHOSPHODIESTERASE 7
  申请人：DARWIN DISCOVERY LTD

  公开号：WO2001074786A1

  公开（公告）日：2001-10-11

  Compounds of formula (1) are described, wherein R1 represents an aryl or heteroaryl group; A, B, D and E, which may be the same or different, each represents a nitrogen atom or a C(R2) group [in which R2 is a hydrogen or halogen atom or an alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxy, -NO¿2? or -CN group] provided that two or more of A, B, D and E are C(R?2¿) groups; X represents an oxygen or sulphur atom or a N(R3) group in which R3 is a hydrogen atom or an alkyl group; Q, R, S and T, which may be the same or different each represents a nitrogen atom or a group C(R4) [in which R4 is an atom or group -L1(Alk1)rL2(R5)S], provided that two or more of Q, R, S and T are C(R4) groups. The compounds are potent and selective inhibitors of the enzyme phosphodiesterase 7 and are of use in the treatment of autoimmune and other diseases in which inhibition of the enzyme can have a beneficial effect.